"Accelerating Overseas Market Expansion as Exports to China Begin in Earnest"

Huons Biopharma, a subsidiary of Huons Group specializing in botulinum toxin, announced on April 14 that Junghee Lee has been appointed as its new CEO.

Junghee Lee, CEO of Huons Biopharma. Huons Biopharma

Junghee Lee, CEO of Huons Biopharma. Huons Biopharma

View original image

The newly appointed CEO, Junghee Lee, born in 1976, holds an MBA from Aalto University in Finland (formerly Helsinki School of Economics). Over the past 23 years, Lee has built expertise in marketing, sales, and strategic planning in the dermatological and aesthetic medicine markets, having worked at Ipsen Korea, Hanwha Pharm, Hugel, Daewoong Pharmaceutical, Jetema, and Chong Kun Dang Bio. While at Hugel and Daewoong Pharmaceutical, Lee was in charge of overseas business development and is credited with laying the foundation for global market expansion.


In January, Huons Biopharma received product approval from the National Medical Products Administration (NMPA) of China for its botulinum toxin, Hutox® (marketed domestically as Liztox·LIZTOX®) in the 100-unit dosage, and began its first shipments last month.


CEO Lee stated, "Huons Biopharma is at a critical juncture as we have obtained product approval for our botulinum toxin in China and are beginning to accelerate exports. In the second half of this year, we will actively pursue exports to China and expand research and development for next-generation products, making every effort to ensure sustainable growth."



Huons Biopharma currently sells its products in 16 countries, including Thailand and Russia. The company plans to further expand its global sales, focusing on South America, the Middle East, and Southeast Asia.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing